Advertisement

Topics

FDA approves apalutamide for non-metastatic castration-resistant prostate cancer

10:05 EST 15 Feb 2018 | ecancermedicalscience

The U.S. Food and Drug Administration has approved apalutamide for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Approval was based on a multicenter, double-blind, clinical trial (SPARTAN, NCT01946204) randomizing 1,207...

Original Article: FDA approves apalutamide for non-metastatic castration-resistant prostate cancer

NEXT ARTICLE

More From BioPortfolio on "FDA approves apalutamide for non-metastatic castration-resistant prostate cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...